Evidence map›Paper›PMID 40325426›Full record

ArticleBMC medicine2025

Dissecting the clinical and pathological prognosis of MCI patients who reverted to normal cognition: a longitudinal study.

Hai-Hong Yu, Lan Tan, Meng-Jiao Jiao, Yi-Ju Lv, Xin-Hao Zhang, Chen-Chen Tan, Wei Xu, Alzheimer’s Disease Neuroimaging Initiative

Abstract read
In one paragraph

Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hai-Hong YuDepartment of Neurology, Qingdao Municipal Hospital, Qingdao University, Donghai Middle Road, No.5, Qingdao, China.
Lan TanDepartment of Neurology, Qingdao Municipal Hospital, Qingdao University, Donghai Middle Road, No.5, Qingdao, China.
Meng-Jiao JiaoMedical College, Qingdao University, Qingdao, China.
Yi-Ju LvMedical College, Qingdao University, Qingdao, China.
Xin-Hao ZhangMedical College, Qingdao University, Qingdao, China.
Chen-Chen TanDepartment of Neurology, Qingdao Municipal Hospital, Qingdao University, Donghai Middle Road, No.5, Qingdao, China.
Wei XuDepartment of Neurology, Qingdao Municipal Hospital, Qingdao University, Donghai Middle Road, No.5, Qingdao, China. dr_xuwei@qdu.edu.cn.
Alzheimer’s Disease Neuroimaging Initiative

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
National Natural Science Foundation of China 82001136NIA NIH HHS U01 AG024904Taishan Scholar Project of Shandong Province tsqn202211375
6 · The paper itself

Abstract

backgroundControversy existed in the prognosis of reversion from mild cognitive impairment (MCI) to normal cognition (NC). We aim to depict the prognostic characteristics of cognition, neuroimaging, and pathology biomarkers, as well as the risk of Alzheimer's disease (AD) dementia for MCI reverters.

methodsA total of 796 non-demented participants (mean age = 73.3 years, female = 54.4%, MCI = 55.7%), who were divided into MCI reverters (n = 109), stable MCI (n = 334), and stable NC (n = 353) based on 2-year diagnosis changes, were subsequently followed up for 6 years. Cox proportional hazard regression models were applied to assess the AD dementia hazard. Linear mixed-effect models were used to evaluate the differences in changing rates of cognitive scores, brain volumes, brain metabolism, and AD biomarkers among three groups.

resultsThe 2-year MCI reversion rate was 18.17%. MCI reversion was associated with an 89.6% lower risk of AD dementia (HR = 0.104, 95% confidence interval = [0.033, 0.335], p < 0.001) than stable MCI. No significant difference in incident AD risk was found between MCI reverters and stable NC (p = 0.533). Compared to stable MCI, reverters exhibited slower decreases in cognitive performance (false discovery rate corrected p value [FDR-Q] < 0.050), brain volumes (FDR-Q < 0.050), brain metabolism (FDR-Q < 0.001), and levels of cerebrospinal fluid β-amyloid

conclusionsReversion from MCI to NC predicts a favorable prognosis of pathological, neurodegenerative, and cognitive trajectory.

Indexed as

Alzheimer DiseaseCognitionCognitive DysfunctionAgedAged, 80 and overAmyloid beta-PeptidesBiomarkersBrainDisease ProgressionFemaleHumansLongitudinal StudiesMalePrognosisAmyloid beta-PeptidesBiomarkersMild cognitive impairment; Reversion; Dementia; Prognosis; Biomarker

Identifiers

PMID40325426
PMCPMC12054060

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.